"CVS Health found that among the 65 million members covered by CVS Health's pharmacy benefit management business, prescription volume of Harvoni at eight weeks following its launch was roughly 2.5 times greater than Sovaldi's prescription rate eight weeks following its launch in December 2013. The number of Harvoni prescriptions at eight weeks totaled over 7,500, while Sovaldi's scripts totaled just more than 3,000 at the same point following its launch."
Less pills to take and more effective. Only pushback was the price but that didn't stop Harvoni from outselling Sovaldi eight weeks into launch. Who's gonna go with the older less effective solution for their health.
They'll eventually work out the pricing issues but Harvoni will still be Harvoni and Sovaldi will still be Sovaldi.
GILD
News 
Market Data 
Discover 
